Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,243
  • Shares Outstanding, K 410,672
  • Annual Sales, $ 306,910 K
  • Annual Income, $ -59,110 K
  • 60-Month Beta 1.98
  • Price/Sales 1.28
  • Price/Cash Flow N/A
  • Price/Book 0.71
Trade AMRN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings $0.00 on 02/29/24
  • Latest Earnings Date 05/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 109.40% ( +8.44%)
  • Historical Volatility 69.28%
  • IV Percentile 65%
  • IV Rank 33.23%
  • IV High 277.98% on 10/31/23
  • IV Low 25.49% on 11/16/23
  • Put/Call Vol Ratio 3.99
  • Today's Volume 759
  • Volume Avg (30-Day) 854
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 43,101
  • Open Int (30-Day) 40,165

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8221 +11.74%
on 03/18/24
1.1100 -17.24%
on 04/09/24
+0.0597 (+6.95%)
since 03/15/24
3-Month
0.8015 +14.61%
on 03/14/24
1.3700 -32.95%
on 01/30/24
-0.2614 (-22.15%)
since 01/12/24
52-Week
0.6510 +41.11%
on 11/01/23
1.4850 -38.14%
on 07/18/23
-0.4314 (-31.96%)
since 04/14/23

Most Recent Stories

More News
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

AMRN : 0.9186 (-4.01%)
HLS.TO : 4.94 (-4.45%)
Why Amarin Stock Was Rocketing Higher on Wednesday

There was unambigously good news about the company's single commercialized medication.

AMRN : 0.9186 (-4.01%)
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

AMRN earnings call for the period ending December 31, 2023.

AMRN : 0.9186 (-4.01%)
Why Amarin Stock Skyrocketed Today

The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.

AMRN : 0.9186 (-4.01%)
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript

AMRN earnings call for the period ending September 30, 2023.

AMRN : 0.9186 (-4.01%)
Why Amarin Stock Is Sinking Today

The drugmaker announced a major corporate reorganization and a new CEO.

AMRN : 0.9186 (-4.01%)
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript

AMRN earnings call for the period ending March 31, 2023.

AMRN : 0.9186 (-4.01%)
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

AMRN : 0.9186 (-4.01%)
RCUS : 16.29 (-1.75%)
ALLO : 3.55 (-6.58%)
OCUP : 1.7600 (-4.35%)
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

UTHR : 235.08 (+1.07%)
PCRX : 26.53 (-1.12%)
AMRN : 0.9186 (-4.01%)
CORT : 23.15 (-1.53%)
IONS : 41.55 (-0.46%)
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.

VRTX : 397.36 (+0.20%)
AMRN : 0.9186 (-4.01%)
CRSP : 58.72 (-3.21%)
ALLO : 3.55 (-6.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating...

See More

Key Turning Points

3rd Resistance Point 1.0513
2nd Resistance Point 1.0207
1st Resistance Point 0.9696
Last Price 0.9186
1st Support Level 0.8879
2nd Support Level 0.8573
3rd Support Level 0.8062

See More

52-Week High 1.4850
Fibonacci 61.8% 1.1664
Fibonacci 50% 1.0680
Fibonacci 38.2% 0.9696
Last Price 0.9186
52-Week Low 0.6510

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar